Enliven Therapeutics, Inc.
ELVN
$21.00
$0.442.14%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 12.99% | -26.99% | -25.53% | -19.67% | -11.49% |
| Total Depreciation and Amortization | -22.50% | 3.85% | -6.33% | 2.56% | 2.56% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 18.13% | 106.33% | 73.89% | 376.00% | 258.36% |
| Change in Net Operating Assets | -103.15% | 107.14% | 46.15% | -109.33% | 58.25% |
| Cash from Operations | -8.91% | 16.53% | -3.28% | -37.82% | 23.29% |
| Capital Expenditure | 104.55% | -6,850.00% | 0.00% | 100.00% | -37.50% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -127.34% | -444.96% | 108.10% | -98.12% | 141.79% |
| Cash from Investing | -127.37% | -445.34% | 107.98% | -98.12% | 141.71% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | 11,991.81% | -99.74% | 44,313.33% | -99.31% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -132.95% | 11,991.81% | -99.74% | 44,313.33% | 362.82% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -572.13% | 133.91% | -145.83% | -10.64% | 107.23% |